RE:RE:Dapaglifizin from AZWex in preclinical you have certain off-targets that you want to avoid for hearth failure etc cases especially. By previouss sglt2 drugs it is shown that inhibiting sglt2 (assuming that drug is not chemically super different from Sirona's) is Ok. The issue is toxicity due to its function, urinary track infections etc as MWM pointed out. May be drug will work for diabetes but also increase UT infections would you still approve? This will depend on data and no one can comment on that before ph 1 (better ph 2) data min a year or two. It is not risk free that is why I said normally less than 10% chance but in this case may be 30%.
For possible tox (source not academic but fine)
https://www.medicinenet.com/sglt2_inhibitors_type_2_diabetes_drug_class/article.htm
Serious side effects of SGLT2 inhibitors include:
MWM also ponted about amputation risk which is recently included
https://www.diabetesincontrol.com/uncommon-side-effect-amputation-risk-with-canagliflozin/
For 1067 trial even if such test would take short time (4 to 8 weeks) the whole regulatory process is not short and could take 6 months to a year. See the cases
https://clinicaltrials.gov/ct2/show/NCT01016080
https://clinicaltrials.gov/ct2/show/NCT01249469